Summary

Report Scope
The report provides an overview of the global diabetes therapeutics and diagnostics market and analyzes market trends. It includes global revenue ($ million) using 2024 as the base year, estimated data for 2025, and projected data for 2026 through 2030.
The market is segmented by product and end-user. The diabetes market by product is divided into three segments: diabetes therapeutics, diabetes monitoring devices and accessories, and insulin delivery devices. Diabetes therapeutics encompass injectable therapies, such as Glucagon-Like Peptide-1 (GLP-1) and insulin, as well as oral antidiabetic drugs (OADs). Diabetes monitoring devices are categorized into blood glucose test strips (BGTS), blood glucose meters, lancets and lancet devices, and continuous glucose monitoring (CGM) systems. Insulin delivery devices are further divided into insulin pumps, insulin pens and needles, insulin syringes, and other products. Based on end users, the market is segmented into hospitals and clinics, home care settings, and diagnostic centers. Geographical regions covered in this study are North America (the U.S., Canada and Mexico), Europe (Germany, the U.K., Italy, France, Spain and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia and the Rest of Asia-Pacific), the Middle East and Africa (MEA), and South America, focusing on all the major countries in these regions.
This study further focuses on the driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and providing the leading global companies in diabetes therapeutics and diagnostics. It also contains a dedicated section of company profiles that covers companies' overviews, key financials, product portfolios and recent developments.

Report Includes
- 161 data tables and 72 additional tables
- In-depth analysis of the global markets for diabetes therapeutics and diagnostics
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects of the global market, along with a market share analysis by product type, end user and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of various macroeconomic variables
- Insights derived from Porter's Five Forces model, as well as global supply chain analysis
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companies' market shares, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Abbott, Dexcom, Novo Nordisk A/S, Eli Lilly and Co., and Sanofi

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Technological Advances
Conclusion
Chapter 2 Market Overview
Overview
Epidemiology of Diabetes
Regional Distribution
Gender Distribution
Porter's Five Forces Analysis
Potential for New Entrants (Low to Moderate)
Bargaining Power of Suppliers (Low to Moderate)
Bargaining Power of Buyers (High)
Threat of Substitutes (Low)
Competition in the Industry (Low to Moderate)
Macroeconomic Factors Analysis
Healthcare Spending
Insurance Coverage and Reimbursement Policies
Technological Advances
The U.S. Tariff Scenario
Chapter 3 Market Dynamics
Overview
Market Drivers
Increasing Prevalence of Diabetes
Growing Geriatric Population
Changing Lifestyle Habits
Market Restraints
High Cost of Diabetes Care
Limited Healthcare Access in Low- and Middle-Income Countries
Market Opportunities
Integration of AI, IoT and Wearables for Remote Monitoring
Government Funding and Initiatives
Growing Public-Private Partnerships and Industry Collaborations
Market Challenges
Data Privacy and Cybersecurity Risks
Shortage of Skilled Professionals
Chapter 4 Regulatory Landscape
Regulatory Frameworks
U.S.
Europe
Other Regions
Chapter 5 Emerging Technologies and Developments
Emerging Technologies
Next-Generation Insulin Delivery Systems
Multi-GLP Agonist
Non-Invasive Glucose Monitoring
Artificial Intelligence
Analysis of Clinical Trials
Key Takeaways
Analysis of Clinical Trials by Type of Study
Clinical Trials Analysis by Status
Clinical Trials Analysis by Phase
Patent Analysis
Key Takeaways
Patents, by Year
Patents, by Leading Applicant
Patents, by Leading Patent Holder
Patents, by Jurisdiction
Chapter 6 Market Segment Analysis
Segmentation Breakdown
Global Diabetes Therapeutics and Diagnostic Market, by Product
Key Takeaways
Diabetes Therapeutics
Diabetes Monitoring Devices and Accessories
Insulin Delivery Devices
Global Diabetes Therapeutics and Diagnostic Market, by End User
Key Takeaways
Home Care Setting
Hospitals and Clinics
Diagnostic Centers
Geographic Breakdown
Global Diabetes Therapeutics and Diagnostic Market, by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Landscape
Leading Companies
Novo Nordisk A/S
Lilly
Abbott
Dexcom
Medtronic
Embecta Corp.
Key Strategic Developments
Chapter 8 Sustainability in the Diabetes Therapeutics and Diagnostics Market: An ESG Perspective
Introduction to ESG
ESG in Diabetes Therapeutics and Diagnostics
Key ESG Issues
ESG Performance Analysis
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC
Chapter 9 Appendix
Methodology
Sources
Abbreviations
Company Profiles
ABBOTT
ASTRAZENECA
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
B. BRAUN SE
DEXCOM INC.
EMBECTA CORP.
F. HOFFMANN-LA ROCHE LTD.
INSULET CORP.
LIFESCAN IP HOLDINGS LLC.
LILLY USA LLC.
MEDTRONIC
MERCK & CO. INC.
NOVO NORDISK A/S
SANOFI
TERUMO CORP.
Few Emerging Start-ups/Market Disruptors

ページTOPに戻る

List of Tables/Graphs

List of Tables

Summary Table : Global Market for Diabetes Therapeutics and Diagnostics, by Region, Through 2030
Table 1 : Global Prevalence of Diabetes (Ages 20–79), by Region, 2024 vs. 2050
Table 2 : Porter’s Five Forces Analysis: Overview
Table 3 : Global: Diabetes Related Expenditure, 2024
Table 4 : Diabetes: Geriatric Overview, 2024 and 2050
Table 5 : Geriatric Diabetes Management
Table 6 : Global Estimates and Projections of Numbers and Prevalence of Adults (Aged 20+) With High BMI, by Sex, 2010, 2015 and 2030
Table 7 : Indonesia: Price Ranges of Diabetes Monitoring Products, by Sector, 2024
Table 8 : Undiagnosed Diabetes by World Bank Income Classification, 2025
Table 9 : Selected Technology Integrated Products
Table 10 : Diabetes: Industry Collaborations, 2024–2025
Table 11 : FDA Medical Device Classification
Table 12 : EU MDR Medical Device Classification
Table 13 : Other Regions: Regulatory Landscape for Anti-Diabetic Drugs
Table 14 : Other Regions: Regulatory Landscape for Diabetic Medical Devices
Table 15 : Non-Invasive Glucose Monitoring Systems
Table 16 : Clinical Trials in Diabetes, by Type of Study, September 2025
Table 17 : Clinical Trials in Diabetes, by Status, September 2025
Table 18 : Clinical Trials in Diabetes, by Phase, September 2025
Table 19 : Number of Diabetes-related Patent Applications, by Leading Applicants, 2021–2024
Table 20 : Number of Diabetes-related Patent Grants, by Top Patent Holder, 2021–2024
Table 21 : Number of Diabetes-related Patent Grants, by Jurisdiction, 2021–2024
Table 22 : Global Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 23 : Global Revenues of Leading Diabetes-Focused Pharmaceutical Companies, 2024 vs. 2023
Table 24 : Major Companies: Diabetes Therapeutic Pipeline
Table 25 : Global Market for Diabetes Therapeutics, by Type, Through 2030
Table 26 : Insulin vs. GLP-1 Therapy
Table 27 : Global Market for Injectable Diabetes Therapies, by Type, Through 2030
Table 28 : Standard GLP-1 RAs vs. Dual/Triple Agonists
Table 29 : Comparison of Different Types of Insulins
Table 30 : Oral Antidiabetic Drugs Overview
Table 31 : Global Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 32 : Blood Glucose Test Strips, by Manufacturer
Table 33 : Blood Glucose Meters, by Manufacturer
Table 34 : Continuous Glucose Monitoring Systems, by Manufacturer
Table 35 : Comparison of Continuous Glucose Monitoring Systems, by Company
Table 36 : Lancets and Lancet Devices, by Manufacturer
Table 37 : Global Market for Insulin Delivery Devices, by Type, Through 2030
Table 38 : Insulin Infusion Pumps, by Manufacturer
Table 39 : Insulin Pen, by Manufacturer
Table 40 : Global Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 41 : Global Market for Diabetes Therapeutics and Diagnostics, by Region, Through 2030
Table 42 : North American Market for Diabetes Therapeutics and Diagnostics, by Country, Through 2030
Table 43 : North American Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 44 : North American Market for Diabetes Therapeutics, by Type, Through 2030
Table 45 : North American Market for Injectable Therapies, by Type, Through 2030
Table 46 : North American Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 47 : North American Market for Insulin Delivery Devices, by Type, Through 2030
Table 48 : North American Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 49 : U.S. Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 50 : U.S. Market for Diabetes Therapeutics, by Type, Through 2030
Table 51 : U.S. Market for Injectable Therapies, by Type, Through 2030
Table 52 : U.S. Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 53 : U.S. Market for Insulin Delivery Devices, by Type, Through 2030
Table 54 : U.S. Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 55 : Canadian Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 56 : Canadian Market for Diabetes Therapeutics, by Type, Through 2030
Table 57 : Canadian Market for Injectable Therapies, by Type, Through 2030
Table 58 : Canadian Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 59 : Canadian Market for Insulin Delivery Devices, by Type, Through 2030
Table 60 : Canadian Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 61 : Mexican Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 62 : Mexican Market for Diabetes Therapeutics, by Type, Through 2030
Table 63 : Mexican Market for Injectable Therapies, by Type, Through 2030
Table 64 : Mexican Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 65 : Mexican Market for Insulin Delivery Devices, by Type, Through 2030
Table 66 : Mexican Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 67 : European Market for Diabetes Therapeutics and Diagnostics, by Country, Through 2030
Table 68 : European Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 69 : European Market for Diabetes Therapeutics, by Type, Through 2030
Table 70 : European Market for Injectable Therapies, by Type, Through 2030
Table 71 : European Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 72 : European Market for Insulin Delivery Devices, by Type, Through 2030
Table 73 : European Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 74 : German Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 75 : German Market for Diabetes Therapeutics, by Type, Through 2030
Table 76 : German Market for Injectable Therapies, by Type, Through 2030
Table 77 : German Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 78 : German Market for Insulin Delivery Devices, by Type, Through 2030
Table 79 : German Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 80 : U.K. Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 81 : U.K. Market for Diabetes Therapeutics, by Type, Through 2030
Table 82 : U.K. Market for Injectable Therapies, by Type, Through 2030
Table 83 : U.K. Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 84 : U.K. Market for Insulin Delivery Devices, by Type, Through 2030
Table 85 : U.K. Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 86 : French Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 87 : French Market for Diabetes Therapeutics, by Type, Through 2030
Table 88 : French Market for Injectable Therapies, by Type, Through 2030
Table 89 : French Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 90 : French Market for Insulin Delivery Devices, by Type, Through 2030
Table 91 : French Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 92 : Italian Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 93 : Italian Market for Diabetes Therapeutics, by Type, Through 2030
Table 94 : Italian Market for Injectable Therapies, by Type, Through 2030
Table 95 : Italian Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 96 : Italian Market for Insulin Delivery Devices, by Type, Through 2030
Table 97 : Italian Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 98 : Spanish Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 99 : Spanish Market for Diabetes Therapeutics, by Type, Through 2030
Table 100 : Spanish Market for Injectable Therapies, by Type, Through 2030
Table 101 : Spanish Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 102 : Spanish Market for Insulin Delivery Devices, by Type, Through 2030
Table 103 : Spanish Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 104 : Rest of Europe Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 105 : Rest of Europe Market for Diabetes Therapeutics, by Type, Through 2030
Table 106 : Rest of Europe Market for Injectable Therapies, by Type, Through 2030
Table 107 : Rest of Europe Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 108 : Rest of Europe Market for Insulin Delivery Devices, by Type, Through 2030
Table 109 : Rest of Europe Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 110 : Asia-Pacific Market for Diabetes Therapeutics and Diagnostics, by Country, Through 2030
Table 111 : Asia-Pacific Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 112 : Asia-Pacific Market for Diabetes Therapeutics, by Type, Through 2030
Table 113 : Asia-Pacific Market for Injectable Therapies, by Type, Through 2030
Table 114 : Asia-Pacific Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 115 : Asia-Pacific Market for Insulin Delivery Devices, by Type, Through 2030
Table 116 : Asia-Pacific Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 117 : Japanese Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 118 : Japanese Market for Diabetes Therapeutics, by Type, Through 2030
Table 119 : Japanese Market for Injectable Therapies, by Type, Through 2030
Table 120 : Japanese Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 121 : Japanese Market for Insulin Delivery Devices, by Type, Through 2030
Table 122 : Japanese Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 123 : Chinese Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 124 : Chinese Market for Diabetes Therapeutics, by Type, Through 2030
Table 125 : Chinese Market for Injectable Therapies, by Type, Through 2030
Table 126 : Chinese Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 127 : Chinese Market for Insulin Delivery Devices, by Type, Through 2030
Table 128 : Chinese Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 129 : Indian Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 130 : Indian Market for Diabetes Therapeutics, by Type, Through 2030
Table 131 : Indian Market for Injectable Therapies, by Type, Through 2030
Table 132 : Indian Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 133 : Indian Market for Insulin Delivery Devices, by Type, Through 2030
Table 134 : Indian Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 135 : South Korean Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 136 : South Korean Market for Diabetes Therapeutics, by Type, Through 2030
Table 137 : South Korean Market for Injectable Therapies, by Type, Through 2030
Table 138 : South Korean Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 139 : South Korean Market for Insulin Delivery Devices, by Type, Through 2030
Table 140 : South Korean Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 141 : Australian Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 142 : Australian Market for Diabetes Therapeutics, by Type, Through 2030
Table 143 : Australian Market for Injectable Therapies, by Type, Through 2030
Table 144 : Australian Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 145 : Australian Market for Insulin Delivery Devices, by Type, Through 2030
Table 146 : Australian Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 147 : Rest of Asia-Pacific Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 148 : Rest of Asia-Pacific Market for Diabetes Therapeutics, by Type, Through 2030
Table 149 : Rest of Asia-Pacific Market for Injectable Therapies, by Type, Through 2030
Table 150 : Rest of Asia-Pacific Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 151 : Rest of Asia-Pacific Market for Insulin Delivery Devices, by Type, Through 2030
Table 152 : Rest of Asia-Pacific Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 153 : MEA Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 154 : MEA Market for Diabetes Therapeutics, by Type, Through 2030
Table 155 : MEA Market for Injectable Therapies, by Type, Through 2030
Table 156 : MEA Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 157 : MEA Market for Insulin Delivery Devices, by Type, Through 2030
Table 158 : MEA Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 159 : South American Market for Diabetes Therapeutics and Diagnostics, by Product, Through 2030
Table 160 : South American Market for Diabetes Therapeutics, by Type, Through 2030
Table 161 : South American Market for Injectable Therapies, by Type, Through 2030
Table 162 : South American Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2030
Table 163 : South American Market for Insulin Delivery Devices, by Type, Through 2030
Table 164 : South American Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2030
Table 165 : Global Market Share Analysis for Diabetes Therapeutics, 2024
Table 166 : Global Market Share Analysis for Diabetes Monitoring Devicesand Accessories, 2024
Table 167 : Global Market Share Analysis for Insulin Delivery Devices, 2024
Table 168 : Diabetes Therapeutics and Diagnostics: Recent Strategic Developments, 2025
Table 169 : Diabetes Waste Management Recommendations
Table 170 : ESG Rankings for Diabetes Therapeutics and Diagnostics Companies, 2025*
Table 171 : ESG: Environmental Overview
Table 172 : ESG: Social Overview
Table 173 : ESG: Governance Overview
Table 174 : Information Sources for this Report
Table 175 : Abbreviations Used in the Global Diabetes Therapeutics and Diagnostics Market Report
Table 176 : Abbott: Company Snapshot
Table 177 : Abbott: Financial Performance, FY 2023 and 2024
Table 178 : Abbott: Product Portfolio
Table 179 : Abbott: News/Key Developments, 2023–2025
Table 180 : AstraZeneca: Company Snapshot
Table 181 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 182 : AstraZeneca: Product Portfolio
Table 183 : AstraZeneca: News/Recent Developments, 2023–2024
Table 184 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 185 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2023 and 2024
Table 186 : Boehringer Ingelheim International GmbH: Product Portfolio
Table 187 : B. Braun SE: Company Snapshot
Table 188 : B. Braun SE: Financial Performance, FY 2023 and 2024
Table 189 : B. Braun SE: Product Portfolio
Table 190 : Dexcom Inc.: Company Snapshot
Table 191 : Dexcom Inc.: Financial Performance, FY 2023 and 2024
Table 192 : Dexcom Inc.: Product Portfolio
Table 193 : Dexcom Inc.: News/Key Developments, 2024–2025
Table 194 : Embecta Corp.: Company Snapshot
Table 195 : Embecta Corp.: Financial Performance, FY 2023 and 2024
Table 196 : Embecta Corp.: Product Portfolio
Table 197 : Embecta Corp.: News/Key Developments, 2023–2024
Table 198 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 199 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 200 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 201 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024–2025
Table 202 : Insulet Corp.: Company Snapshot
Table 203 : Insulet Corp.: Financial Performance, FY 2023 and 2024
Table 204 : Insulet Corp.: Product Portfolio
Table 205 : Insulet Corp.: News/Key Developments, 2023–2025
Table 206 : LifeScan IP Holdings LLC.: Company Snapshot
Table 207 : LifeScan IP Holdings LLC.: Product Portfolio
Table 208 : Lilly USA LLC.: Company Snapshot
Table 209 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 210 : Lilly USA LLC.: Product Portfolio
Table 211 : Lilly USA LLC.: News/Key Developments, 2023
Table 212 : Medtronic: Company Snapshot
Table 213 : Medtronic: Financial Performance, FY 2023 and 2024
Table 214 : Medtronic: Product Portfolio
Table 215 : Medtronic: News/Key Developments, 2023-2025
Table 216 : Merck & Co. Inc.: Company Snapshot
Table 217 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 218 : Merck & Co. Inc.: Product Portfolio
Table 219 : Merck & Co. Inc.: News/Key Developments, 2025
Table 220 : Novo Nordisk A/S: Company Snapshot
Table 221 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 222 : Novo Nordisk A/S: Product Portfolio
Table 223 : Novo Nordisk A/S: News/Key Developments, 2024–2025
Table 224 : Sanofi: Company Snapshot
Table 225 : Sanofi: Financial Performance, FY 2023 and 2024
Table 226 : Sanofi: Product Portfolio
Table 227 : Sanofi: News/Key Developments, 2024–2025
Table 228 : Terumo Corp.: Company Snapshot
Table 229 : Terumo Corp.: Financial Performance, FY 2023 and 2024
Table 230 : Terumo Corp.: Product Portfolio
Table 231 : Terumo Corp.: News/Key Developments, 2023
Table 232 : List of a Few Emerging Start-ups/Market Disruptors